alendronate has been researched along with Myelodysplastic Syndromes in 1 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addressing key issues of reducing toxic side effects and improving pharmacokinetic profiles of the therapeutic agents, we have developed a new formulation by co-packaging DAC and ATO into alendronate-conjugated bone-targeting nanoparticles (BTNPs)." | 1.46 | Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity. ( Ferrari, M; Hu, Z; Nizzero, S; Ramirez, MR; Shen, H; Shi, C; Wu, X; Zhang, G; Zhou, J, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, X | 1 |
| Hu, Z | 1 |
| Nizzero, S | 1 |
| Zhang, G | 1 |
| Ramirez, MR | 1 |
| Shi, C | 1 |
| Zhou, J | 1 |
| Ferrari, M | 1 |
| Shen, H | 1 |
1 other study available for alendronate and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
Topics: Alendronate; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptos | 2017 |